Turn Therapeutics™ Closes Series B Round

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

Turn Therapeutics™, Inc., is a Los Angeles-based pharmaceutical and medical device company. Today they announced the closing of its fully-subscribed series B financing. The capital raised will fund a large-scale, pre-launch, phase 4 trial for AtopX™ Eczema Emulsion, with enrollment scheduled to begin in Q1, 2020. The series B financing will also support advancement of additional infectious disease and dermatology programs based on Turn’s proprietary PermaFusion™ technology platform.

“AtopX™ is an extensively-studied, well-tolerated, non-steroidal, FDA cleared product indicated for the management of atopic, irritant, and radiation dermatitis. With this new capital, we will commence a large-scale, phase 4 trial specifically for the management of atopic dermatitis that will support the planned launch of AtopX™ in this high need space. We expect AtopX™ to be well-received by the commercial market due to its ease of use and substantial safety profile,” says Bradley Burnam, CEO of Turn Therapeutics™.

The phase 4, adaptive trial design will assess safety and efficacy of AtopX™ in moderate to severe eczema patients as its primary endpoint, as well as employ the traditional quality of life and comfort indexes typical of such trials. In addition, the company will continue to advance its pipeline infectious disease and dermatology programs, including new drug candidates to treat shingles of the eye and onychomycosis.

The Series B round included investment from existing investors and new, high-level family office investors with expertise in the biotech space. The round closed on September 30, 2019.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.